Angli Kang: Cefixime Granules Obtained the Drug Registration Certificate

2026-03-20 12:13:06

Onli康 announces that recently, the company received the “Drug Registration Certificate” for Cefixime Granules issued by the National Medical Products Administration. Cefixime Granules are used to treat bacterial infections caused by sensitive strains of bacteria such as Streptococcus (excluding Enterococcus), Streptococcus pneumoniae, Neisseria gonorrhoeae, Haemophilus parainfluenzae, Escherichia coli, Klebsiella, Shigella, Proteus, and Haemophilus influenzae, including: acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, cystitis, pyelonephritis, gonococcal urethritis, cholecystitis, cholangitis, otitis media, sinusitis, and scarlet fever.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.